Subsequently a 6-gene prediction model was constructed which is capable of distinguishing MF and ID cases with unprecedented accuracy. This model correctly predicted the class of 97% of cases in a blind test validation using 24 MF patients with low clinical stages.
INTRODUCTION
Mycosis fungoides (MF) is a peripheral T-cell lymphoma (CTCL) characterized by the infiltration and accumulation of tumoral T cells in the skin (epidermal and dermal infiltration) 1 . It is the most frequent type of CTCL, representing more than half of all lymphomas originating in the skin 2 .
Clinical and pathological diagnosis of MF has proved very difficult since it bears many resemblances to common inflammatory dermatoses (ID) such as interface and spongiotic dermatitis, conditions involving infiltration and accumulation of benign T cells in the skin.
The study of MF is further compounded by the small number of tumoral cells, which may be present in the skin, with tumoral T-cell infiltrate often accounting for only 5-10% of the total tissue cells. Most CTCL have the phenotype of T-helper memory lymphocytes (CD3+, CD4+)
with only a minority of cases showing phenotypes such as CD4-or CD8+ with CD8+ cases possibly representing a subset of aggressive cases 3 . Additionally loss of CD7-expression is considered a distinguishing characteristic of MF 4 .
The etiology of MF remains largely unknown, although some triggering factors such as chronic antigen stimulation 5 or human T cell lymphotropic virus type 1 (HTLV-1) or other viral infections have been proposed. However, some of these findings have been somewhat contentious 6, 7 . Molecular studies of MF have revealed some interesting facts, although the studies are confined to small groups of genes and proteins. Defective FAS signaling has been suggested as a possible causative agent in MF pathogenesis due to defects in apoptosis signaling in skin homing T-cells 8 . Reduction of FAS expression has been documented in peripheral blood CD4+ T lymphocytes in CTCL 9 . This decreased FAS expression may be the result of FAS mutations which are infrequent but are present in some cases 8 . Defective FAS signaling may also be supplemented by mutations or defects in caspases or BCL2 family members. However studies of BCL2 10 and BAX 8 do not favor a role of alterations in these genes in MF pathogenesis. Similarly molecular analysis of P53, the most frequently mutated gene in human malignancies, has shown that mutations are found only at later stages of disease and are unlikely to play a role in the early pathogenesis of MF 8 . Studies of P16 have revealed reduced p16 expression in progressing MF lesions 11, 12 and some studies have also revealed silencing of p15 gene expression associated with MF and Sezary syndrome 13 .
For personal use only. on . by guest www.bloodjournal.org From Additional studies have implicated STAT1 14 , STAT3 15 , CD30 16 , CD40/CD40L 17 , IL15 18 , IL16 18 , chemokine receptors 19 and telomere shortening and increased telomerase activity 20 in pathogenesis and progression of MF. Finally in vitro studies of MF have shown that NFkappaB may play a role in the pathogenesis of MF 21 Here we have focused on the mechanisms of tumorigenesis of MF and MF heterogeneity using cDNA microarray analysis. The resulting data allows the identification of an MF signature, which can distinguish MF and ID cases using a prediction model, validated in an external blind patient set. cDNA microarrays are a powerful technique, which allow the analysis of the expression of thousands of genes simultaneously. These types of studies have revolutionized the study of cancer allowing finer tumor classification 22 , prediction of treatment response 23, 24 and prediction of overall survival 25 . This type of analysis has been previously used in the in vitro study of MF cells where it was possible to identify genes with a possible role in the resistance to interferon alpha in patient samples 24 . Here these cDNA microarrays have been used for examining the expression profile of a total of 53 MF samples (29 patient study group and an additional 24 patient validation group) and 11 ID samples, allowing the identification of 27 genes implicated in the tumorigenesis of MF many of which are implicated directly in anti-apoptotic signaling by TNF. Subsequently a 6-gene prediction model was identified and validated for both this study group and an external blind set of 24 MF patients. Hierarchical clustering revealed the presence of two main MF groups, whose characteristics have been investigated here. cDNA microarray analysis also allowed the identification of molecular signatures associated with abnormal immunophenotype (11 genes) and tumor stage disease (5 genes).
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Materials and Methods

Case selection
Eleven ID samples, 29 MF samples and 6 normal non-photoexposed control skin samples in addition to a set of 24 MF patients for blind testing were selected from the medical records of hospitals included in the Spanish Tumor Bank Network. All tissue samples, both paraffin embedded and frozen samples, were collected through the protocols of the CNIO tumor bank.
Informed consent was obtained from all patients enrolled in the study under the supervision of the local ethical committees. The MF samples represented consecutive biopsies, randomly chosen, from the contributing hospitals. All samples were centrally reviewed by a panel of pathologists (AMD, JLRP, JFG, JF and MAP), and diagnosed using uniform criteria based on the clinical, histological, immunophenotypical, and molecular characteristics generally accepted and previously defined 26 , with the aid of Hematoxylin/eosin (H/E), CD3, CD4, and 
RNA isolation and cDNA microarray target preparation
Total RNA extraction was carried out using the Trizol reagent (Life technologies, Inc., Grand island, NY) and RNA was further purified using the RNeasy kit (Qiagen Inc., Valencia, CA) and digested with RNase-free DNase I following the manufacturer's instructions. 1-3ug of target RNA was amplified using a T-7 based in vitro transcription system as described previously 24 . Five µg of aRNA from each sample were directly labeled with cyanine 5-conjugated dUTP (Cy5) while 5 µg of aRNA from the Universal Human Reference RNA For all microarray studies the CNIO OncoChip TM was used and hybridizations were performed as previously described 24 . Scanning was performed using a Scanarray 5000 XL (GSI Lumonics, Kanata, Ontario, Canada) and images were analyzed with the GenePix 4.0
Pro Software (Axon Instruments Inc., Union City, CA).
Data analysis and normalization
Fluorescence intensity measurements were subjected to automatic background subtraction and the Cy3/Cy5 ratio values were normalized to the median ratio value of all spots in the array.
The sum of the median background for each channel was calculated and spots with total intensity values below the calculated sum of median backgrounds were discarded. All ratio values were log-transformed (base 2). Inconsistent duplicates were discarded, all consistent duplicate spots and genes were averaged and genes for with less than 80% of the data available were excluded from further analysis 27 . In the case of comparison of immunohistochemical MF subgroups, only genes with 100% of the data available were used.
In order to minimize the background noise caused by the presence of normal cells in the tissue used, two methods were employed: median centering normalization of the genes in all MF and ID cases and normalization of MF and ID samples against a pool of normal skin samples.
The latter method was found to be more effective in separation of MF and ID cases using clustering analysis and therefore each sample in the study was normalized against a collection of normal skin samples. 6 non-photoexposed normal skin samples were chosen and an average for each gene was calculated for those genes for which data was available for at least 4 of the samples. This average was used to normalize all ID and MF samples. All raw data and normalized data is included in the supplementary information (http://bioinfo.cnio.es/data/mycosis_fungoides)
Clustering and statistical analysis
For clustering analysis the SOTA clustering program 28 (http://bioinfo.cnio.es/cgibin/tools/clustering/sotarray) was used and trees were viewed using the TreeView program.
Gene biological functions were assigned by using the GENECARDS database 29 .
(http://bioinformatics.weizmann.ac.il/cards). These procedures are implemented in http://bioinfo.cnio.es/cgi-bin/tools/multest/multest.cgi.
In order to validate the 27-gene MF prediction model, gene clustering was carried out using the self-organizing map algorithm (SOM) 32 defining a maximum of 7 gene clusters. An average for each gene cluster was calculated and this average was used for validation using discriminant analysis in the study group and blind set of patients, utilizing the software SPSS Base version 10.0 (SPSS Inc., Chicago, IL). Additionally, in order to identify a smaller subset of class predictor genes, the gene with the lowest p-value was selected from each SOM cluster. Again these genes were validated by discriminant analysis in both the study set and the blind patient set.
To compare histological and clinical characteristics between the two MF clusters identified the Fisher's Exact test was used.
Immunohistochemistry
Techniques for immunohistochemistry have been previously described 24 . H/E staining of all test group samples was examined to identify cases with tumor type disease compared to plaque type disease and samples containing large cells ( Figure 1 ). Immunohistochemistry and histological assays were performed on the paraffin embedded tissue samples from the test group using commercially available monoclonal CD3, CD8 and Ki67 antibodies 
Results
Data normalization
Preliminary studies were carried out using 6 ID and 8 MF samples. Hierarchical clustering of all MF and ID cases did not separate cases clearly into two groups (Figure 2A ). Taking into account that in some MF and ID cases T cell infiltration accounts for less than 10% of the total tissue, we attempted to eliminate the signal coming from normal surrounding tissue in both sample types. Two methods to reduce background were used; (1) median centering normalization of each gene in MF and ID samples and (2) normalization of each sample against a pool of normal skin samples. Optimal results were achieved using by normalizing each MF and ID sample against a pool of 3 normal non-photoexposed skin samples ( Figure   2B ). Therefore this method of normalization against normal skin samples is a valid method for enriching the data obtained from microarray data in these types of samples where the number of tumoral cells is low, allowing better clustering and classification of these tumors.
For the remainder of the study this type of normalization was used for all cases of MF and ID using a total of 6 normal skin samples for normalization.
Figure 2
Unsupervised clustering of raw and normalized MF and ID data.
A: Using raw data from 8 MF patients and 6 ID patients, group separation was not possible.
B: Normalization of all samples against normal skin allowed the separation of MF from ID cases.
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MF signature: Differential expression with inflammatory skin conditions
To identify genes implicated in MF tumourigenesis a total of 29 samples from MF patients and 11 ID samples were used. Data from microarray studies of each of these cases was normalized against the average signal from 6 normal skin samples. Using a Student's T-test, with an adjusted p-value to control the false discovery rate, 27 genes significant in the separation of MF from ID samples were identified ( Table 1 ). The expression pattern of these 27 genes is notably different between MF and ID cases (Figure 3 ). These genes are involved in a large variety of functions such as cell cycle control, apoptosis and signal transduction.
However the most striking finding is the upregulation of almost 10 genes implicated directly in TNF signaling including genes such as TRAF1, BIRC3 and TNFSF5. 
Figure 3
Using a T statistic and an adjusted p-value, 27 genes significant in the separation of MF from ID samples were identified (29 MF samples, 11 ID samples).
MF prediction model construction and validation by blind testing
Clustering, using the SOM algorithm, of the 27 genes significant in separating MF and ID cases revealed 6 gene clusters (Supplementary  information: http://bioinfo.cnio.es/data/mycosis_fungoides). An average was calculated for each cluster, and using these averages the 27-gene model was validated by discriminant analysis, both in the original sample and in a blind set of 24 MF samples, yielding a success rate of 100% in both cases (Table 2A) . In order to identify a smaller subset of class predictor genes, the gene with the lowest p-value (Table 1) was selected from each of the 6 clusters generated by the SOM algorithm. The final class prediction model of 6 genes (Table 3) was validated by discriminant analysis using only the samples for which all data was available for all 6 genes without imputation of missing values. This class prediction model classifies all cases with 97.3% accuracy in the original sample set and with 97.0% accuracy in the blind set (Table   2B) For 
Identification of MF subgroups
In order to identify subgroups of MF patients, unsupervised hierarchical cluster analysis was performed of all 53 MF samples using data from all genes (3393) for which at least 80% of the data were available, and 2 main subgroups or clusters of MF were identified ( Figure 4A 
Genes implicated in separation of MF immunohistochemical/histological subgroups
The gene expression pattern between aberrant and common phenotype cases and tumor stage and plaque stage disease, were compared using Student's T-tests.
Eleven genes significant in the separation of common phenotype and aberrant phenotype cases were identified ( Figure 5A ), 10 of which were upregulated in aberrant phenotype cases.
Some of the upregulated genes are of unknown function but there are also genes implicated in oncogenesis, signal transduction and protein ubiquitination. 
Discussion
Data normalization
In order to better understand MF tumorigenesis, samples from MF and ID patients have been analyzed using the cDNA microarray CNIO OncoChip TM , which has been specifically designed for the study of cancer 24 . The raw data from each sample was normalized to an average of the signal from a pool of normal non-photoexposed skin samples, in an effort to reduce the signal coming from surrounding normal tissues. This step has allowed the reduction of background noise in these samples where tumoral cells account for less than 10%
of the total cells and subsequent clustering of samples into the correct subgroups. (Figure 2B )
Without this normalization separation of the samples by hierarchical clustering methods was not possible (Figure 2A )
TNF anti -apoptotic pathway activation in the tumorigenesis of MF
Using the normalized microarray data from 29 MF patients and 11 ID patients, 27 genes were identified whose expression is significantly different between MF and ID cases (Table 1, Figure 3 ). Twenty of the 27 genes identified were upregulated in the MF cases while the remaining 7 genes were downregulated in the MF cases.
Most interesting is the observation of the upregulation of almost 10 genes directly implicated in the regulation of TNF signaling including BIRC3, a member of the inhibitor of apoptosis (IAP) gene family, transcriptionally regulated by NF-kappaB 33 . The genes of this family are characterized by the presence of IAP repeat or BIR regions 34 , essential for their antiapoptotic effects 35 . BIRC3 also known as c-IAP2, possesses an anti-apoptotic BIR domain 35 , a caspase binding CARD domain and a RING domain for degradation of target proteins 36 such as caspases 3 and 7 37 ( Figure 6 ).
BIRC1 also known as NAIP, which binds to the cytoplasmic region of TNFR2, the type 2 tumor necrosis family receptor 38 , was also found to be upregulated in MF cases ( Figure 6 ).
However the significance of this upregulation was just outside the adjusted p-value threshold set (p=0.00088, adjusted p=0.100698). Although BIRC1 lacks a CARD domain and a RING domain, it can inhibit caspases 3 and 7 via its BIR domains alone 39 ( Figure 6 ).
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TRAF1 has been identified here as being upregulated in MF cases, this extending previous observations concerning TRAF1 relevance in B-cell lymphomas 40 . TRAF1 is inducible by NF-kappaB 41 and interacts with TNFR2 42 and several TNF family members such as CD40 43, 44 ( Figure 6 ). TNFR2, a receptor of the TNF receptor superfamily lacking an intracellular death domain, mediates survival signaling by recruiting TRAF1, TRAF2 38, 42 and inhibitor of apoptosis proteins such as BIRC3. TNFR2 activates NF-kappaB and JNK survival pathways 38, 42, 45, 46 and the IAP/BIRC protein component of the complex inhibits apoptotic signaling ( Figure 6 ).
The TNF receptor 1, TNFR1 possesses an intracellular death domain and induces apoptosis by recruitment of TRADD and subsequent activation of caspase 8 through the adapter protein FADD 46,47 ( Figure 6 ). However TRAF2 binds with high affinity to TRADD 48 and subsequent recruitment of RIP1, TRAF1 and IAP/BIRC protein family members leads to suppression of apoptotic signaling from this receptor complex 33, 48 . (Figure 6) TNFSF5 (CD40L or TRAP) is a TNF family member implicated in prevention of apoptosis and enhancement of cell proliferation 49, 50 . Expression of CD40L has previously been reported in cases of MF where it was suggested that CD40L might play a role in a paracrine loop important for preventing apoptosis and/or positively regulating growth 17 . It has also been suggested that CD40L expression may be important for homing of neoplastic T cells to the skin 17 . (Figure 6) HCK and oncogene LYN are tyrosine kinases upregulated in MF cases. HCK is responsible for production of TNF in murine cells 51 and both HCK and LYN have been implicated in TNF production in human monocytes 52 . In this study, in addition to HCK and LYN upregulation in MF cases, TNF was overexpressed although significance was just outside the stringent range set here. Additionally HCK 53 and LYN 54 and the oncogene c-MYC 55 are induced by IL2 signaling by JAK2 and STAT4 activation. In this study STAT4 is overexpressed in MF cases, as is the IL2 receptor (IL2R), but with a lower significance.
According to the findings of this study, it is possible that in MF cases, IL2 induced upregulation of HCK and LYN, leads to production of TNF and subsequent anti-apoptotic signaling via TNFR1 and TNRF2 ( Figure 6 ). properties. These include HIC1, LGI1, DLEU1, ST14, MSH5 and PTEN, whose alteration has been described in lymphoid malignancies 59 . However increased expression of numerous oncogenes and positive cell cycle regulators is also observed in this Cluster 1, including growth factors such as those of the fibroblast growth factor family (FGFR1, FGF5), epidermal growth factor family (GRB7, EGFL3, ERBB3), platelet derived growth factor family
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From (PDGFA), vascular endothelial growth factor family (ANGPTL3) and the transforming growth factor family (BMP5, TAB1, TGFBR3, MADHIP, GDF1). In parallel, higher expression of oncogenes (RAB1, RAB14, RABL2B, TIM) and interleukins (IL15RA, IL7, IL1RAPL1, IL11) is observed accompanied by upregulation of positive cell cycle regulators such as cyclin A1, cyclin dependent kinase family genes (CDKL2, CDKL3) and cell division cycle genes (CDC27, CDC20).
Genes associated with aberrant phenotype expression in MF cases
The common phenotype (CD3+/CD4+/CD8-/CD7-) in MF is generally considered to be less aggressive than phenotypes such as CD8+ 3 and/or CD7+ 3,4 and/or CD4- 3, 60 . Corroborating evidence has been found for this in the current study with the upregulation of oncogenes (CSF1R, LHFPL1), cell cycle control genes and transcription factors in cases with aberrant phenotypes ( Figure 5A ). CSF1R is the receptor for colony-stimulating factor 1 and product of the FMS proto-oncogene and its upregulation has previously been described in hematopoietic malignancies 61, 62 .
Genes associated with tumor stage MF disease
Five genes differentially expressed between tumor and plaque stage disease were identified.
( Figure 5C ), all of which are upregulated in cases with tumor stage disease, including IKBKAP , a gene whose overexpression has been shown to block T NF induced NFkappaB activation 63 . However its role its role under normal biological circumstances is unclear.
In conclusion, this study has shown that while tumoral cells account for less than 10% of the total tissue in MF, using microarray studies and normalization against normal skin samples it is possible to detect a signature which distinguishes this type of tumor from common inflammatory skin conditions. This MF signature includes deregulation of TNF signaling in addition to an autocrine TNF feedback loop promoting anti-apoptotic signaling. From this MF signature it was possible to identify a 6-gene MF prediction model which allows 97.3%
accurate distinction from ID cases in the study group, and 97.0% accurate classification in a randomly chosen external blind set of 24 early stage MF patients. These microarray studies allowed the identification of 2 MF subgroups one of which tends to include mainly the aggressive MF cases, and shows increased expression of TNF pathway genes and oncogenes.
